Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting
Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027
Notice of Allowance from the USPTO for patent application covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD-related chronic cough, with patent expected to expire in 2041
Cash runway into 2030 funding key clinical milestones
Management to host a conference call and webcast today at 4:30 p.m. ET
NEW HAVEN, Conn., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio(TM) (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough $(RCC)$, today announced financial results for the quarter ended September 30, 2026, and provided business updates.
"This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials," said Jennifer Good, President and CEO of Trevi Therapeutics. "We also recently aligned with the FDA on our non-IPF ILD-related chronic cough program and expect to initiate a Phase 2 dose-ranging trial in the first quarter of 2027. Chronic cough remains a significant unmet need, and we believe our dual central and peripheral mechanism may be important for the treatment of these patients. The associated respiratory hospitalizations and potential higher risk of lung transplant results in higher cost for IPF and ILD patients, where no FDA-approved therapies exist."
Recent Business Highlights
IPF-Related Chronic Cough
-- The Company is actively recruiting patients with IPF-related chronic
cough in both Phase 3 OCEAN trials. The 12-week fixed-dose OCEAN-2 trial,
was initiated in the third quarter of 2026, and topline results are
expected in the second half of 2027. The 52-week fixed-dose OCEAN-1 trial
was initiated in the second quarter of 2026, and topline results are
expected in the first half of 2028.
Non-IPF ILD-Related Chronic Cough
-- The Company had a positive meeting with the FDA on the non-IPF
ILD-related chronic cough program and gained overall alignment on the
development path forward, including on the Phase 2 dose-ranging trial
design. The Phase 2 trial will evaluate two doses, 54 mg BID and 27 mg
BID, of nalbuphine ER versus placebo, with the primary efficacy endpoint
of relative change from Baseline in 24-hour cough frequency (coughs per
hour), as determined by an objective cough monitor, to be evaluated at 12
weeks of fixed dosing. The trial is expected to enroll approximately 120
patients. The Company expects to initiate the trial in the first quarter
of 2027, subject to review of the trial protocol by the FDA, and topline
results are expected in the first half of 2028.
-- The Company received a Notice of Allowance from the United States Patent
and Trademark Office (USPTO) for a patent application with claims
covering dosing nalbuphine ER in hepatically impaired patients with
non-IPF ILD-related chronic cough. Once issued, the patent is expected to
expire in 2041. Based on our projected product labeling, the Company
believes this patent will be listable on the Orange Book for the non-IPF
ILD-related chronic cough indication.
Refractory Chronic Cough
-- The Company initiated the Phase 2b LAKE trial in patients with RCC in the
second quarter of 2026 and enrollment is progressing. The trial provides
for a sample size re-estimation (SSRE) analysis once 50% of the patients
complete treatment. Based on projected enrollment, the Company now
expects to report the outcome of the SSRE analysis early in the first
quarter of 2027. The Company continues to expect topline results from the
full trial in the second half of 2027.
Third Quarter 2026 Financial Highlights
Cash, cash equivalents and marketable securities: The Company ended the third quarter of 2026 with $299.4 million in cash, cash equivalents and marketable securities.
The Company expects its current cash, cash equivalents and marketable securities will provide cash runway into 2030 and fund the development of Haduvio for the treatment of patients with IPF-related chronic cough, through potential FDA approval. The Company also expects these cash resources will enable the Company to fund the clinical development program through Phase 2 for the treatment of patients with non-IPF ILD-related chronic cough, and the ongoing Phase 2b LAKE trial for the treatment of patients with RCC.
Research and development (R&D) expenses: R&D expenses for the third quarter of 2026 increased to $19.1 million from $10.1 million in the same period in 2025, primarily due to increased clinical development expenses associated with the Phase 3 OCEAN-1 trial, the Phase 2b LAKE trial, and the Phase 3 OCEAN-2 trial as well as increases in stock-based compensation and personnel-related expenses. These increases were partially offset by decreased costs for the Phase 1 NDA supportive studies and the Phase 2b CORAL trial.
General and administrative (G&A) expenses: G&A expenses for the third quarter of 2026 increased to $5.4 million from $3.8 million in the same period in 2025, primarily due to an increase in stock-based compensation and personnel-related expenses.
Other Income, net: Other Income, net for the third quarter of 2026 increased to $3.0 million from $2.1 million in the same period in 2025, primarily due to an increase in interest income from higher invested cash equivalents and marketable securities balances.
Net loss: For the third quarter of 2026, the Company reported a net loss of $21.5 million, compared to a net loss of $11.8 million in the same period in 2025.
Conference Call and Webcast
The Company plans to hold a conference call and webcast to discuss the Company's financial results and business highlights. To register for the live conference call and webcast, please visit the 'Investors & News' section of the Company's website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio(TM) (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a dual acting kappa opioid receptor agonist and a mu opioid receptor antagonist ("KAMA"), hypothesized to reduce cough hypersensitivity by modulating both central neural pathways and peripheral airway nerves. Nalbuphine has been approved and marketed as an injectable for pain indications for decades in the United States ("U.S.") and Europe. Parenteral nalbuphine is not currently scheduled by the U.S. Drug Enforcement Administration and in most of Europe.
Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are 140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are 228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are 2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.
The FDA has conditionally accepted Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
Comments